Good afternoon :)
$
₹
Charles River Laboratories

Charles River Laboratories

CRL

NYSE
Asset Logo

Charles River Laboratories

CRL

NYSE
$279.090.37% (+1.03)
$
₹
$279.090.37% (+1.03)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Diagnostics & Research

Large Cap

With a market cap of $13.4B the stock is ranked 801

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

4.67
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-4.81
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.12
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-5.96%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 19 analysts' reports

Buy
4 analysts
Hold
14 analysts
Sell
1 analyst

Analysts expect a +1.23% price upside over the next year

Current Price$279.09
Target Price$282.42

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and de
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and de

Peers

Peers

Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
35.08
35.08
1Y Return
38.68%
38.68%
Buy Reco %
80.64
80.64
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
30.86
30.86
1Y Return
24.1%
24.1%
Buy Reco %
82.35
82.35
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
33.09
33.09
1Y Return
43.68%
43.68%
Buy Reco %
69.56
69.56
Waters Corporation
WAT
Waters Corporation
P/E Ratio
106.47
106.47
1Y Return
40.14%
40.14%
Buy Reco %
31.81
31.81
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
44.62
44.62
1Y Return
135.31%
135.31%
Buy Reco %
55.00
55.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDiagnostics & Research

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Charles River Laboratories -4.670.12
Thermo Fisher Scientific Inc35.084.571.94
Agilent Technologies Inc30.865.991.29

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

1
0
0.9
-0.2
0.9
-0
1
-0
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue1.011.02110.981.0310.990.991
Net Income0.060.080.06-0.210.020.050.05-0.27-0.01-0
Net Profit Margin6.65%8.76%6.80%-21.51%2.58%5.06%5.41%-27.81%-1.49%-0.14%
See CostsAll values in $ Billion

Frequently asked questions

  1. Charles River Laboratories (CRL) share price today is $279.09 as of September 22, 2026 at 1:30 AM IST. The stock touched a day high of $281.24 and a day low of $276.41.

  2. Charles River Laboratories stock trades on NYSE under the ticker symbol CRL.

  3. Charles River Laboratories's market capitalization is $13.39B as of September 22, 2026 at 1:30 AM IST.

  4. Charles River Laboratories's price-to-earnings (P/E) ratio is N/A as of September 21, 2026.

  5. Charles River Laboratories's price-to-book (P/B) ratio is 4.67 as of September 21, 2026.

  6. Yes, You can buy Charles River Laboratories shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Charles River Laboratories shares in three steps: 1. Search Charles River Laboratories on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Charles River Laboratories trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Charles River Laboratories (CRL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0358 shares at the current price of $279.09.

Loading...